UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer

Seminars in immunopathology, 2019-01, Vol.41 (1), p.21-30

Schmidt, Emmett V.

2019

Volltextzugriff (PDF)

MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses

Science (American Association for the Advancement of Science), 2020-10, Vol.370 (6513), p.241-247

2020

Volltextzugriff (PDF)

The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors

Future oncology (London, England), 2021-02, Vol.17 (6), p.637-648

2021

Volltextzugriff (PDF)

The role of c-myc in cellular growth control

Oncogene, 1999-05, Vol.18 (19), p.2988-2996

Schmidt, E V

1999

Volltextzugriff (PDF)

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials

JAMA network open, 2020-02, Vol.3 (2), p.e1920833-e1920833

2020

Volltextzugriff (PDF)

Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors

PloS one, 2013-04, Vol.8 (4), p.e60838-e60838

2013

Volltextzugriff (PDF)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Journal of clinical oncology, 2020-09, Vol.38 (26), p.2981-2992

2020

Volltextzugriff (PDF)

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

The lancet oncology, 2019-05, Vol.20 (5), p.711-718

2019

Volltextzugriff (PDF)

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-01, Vol.11 (1), p.e005007

2023

Volltextzugriff (PDF)

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Journal of clinical oncology, 2018-11, Vol.36 (32), p.3223-3230

2018

Volltextzugriff (PDF)

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Cancer discovery, 2018-10, Vol.8 (10), p.1250-1257

2018

Volltextzugriff (PDF)

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide

Molecular cancer therapeutics, 2016-08, Vol.15 (8), p.1998-2008

2016

Volltextzugriff (PDF)

Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway

Cell cycle (Georgetown, Tex.), 2009-05, Vol.8 (9), p.1344-1351

2009

Volltextzugriff (PDF)

Hepatitis C virus expression suppresses interferon signaling by degrading STAT1

Gastroenterology (New York, N.Y. 1943), 2005-04, Vol.128 (4), p.1034-1041

2005

Volltextzugriff (PDF)

Drug independence and the curability of cancer by combination chemotherapy

Trends in Cancer, 2022-11, Vol.8 (11), p.915-929

2022

Volltextzugriff (PDF)

Identification of cyclin D1-and estrogen-regulated genes contributing to breast carcinogenesis and progression

Cancer research (Chicago, Ill.), 2006-12, Vol.66 (24), p.11649-11658

2006

Volltextzugriff (PDF)

hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation

Molecular and Cellular Biology, 2005-08, Vol.25 (15), p.6436-6453

2005

Volltextzugriff (PDF)

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-09, Vol.23 (18), p.5349-5357

2017

Volltextzugriff (PDF)

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics

BMC cancer, 2013-02, Vol.13 (1), p.93-93, Article 93

2013

Volltextzugriff (PDF)

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy

Clinical cancer research, 2021-02, Vol.27 (4), p.1019-1028

2021

Volltextzugriff (PDF)

Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System

Journal of Virology, 2002-09, Vol.76 (17), p.8505-8517

2002

Volltextzugriff (PDF)

Cyclin D1 Enhances the Response to Estrogen and Progesterone by Regulating Progesterone Receptor Expression

Molecular and Cellular Biology, 2010-06, Vol.30 (12), p.3111-3125

2010

Volltextzugriff (PDF)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

Journal of clinical oncology, 2023-02, Vol.41 (5), p.974-979

2023

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(149)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(150)

Sprache

Englisch
(150)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(80)
Humans
(60)
Animals
(54)
Mice
(40)
Biological And Medical Sciences
(39)
Oncology
(31)
Female
(26)
Mice, Transgenic
(26)
Tumors
(24)
Medical Sciences
(23)
Biochemistry & Molecular Biology
(19)
Fundamental And Applied Biological Sciences. Psychology
(18)
Cell Biology
(15)
Male
(13)
Rna, Messenger - Genetics
(13)
Gene Expression
(12)
Cancer
(11)
Cyclin D1
(11)
Immunology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses

The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors

The role of c-myc in cellular growth control

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials

Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide

Growth controls connect: Interactions between c-myc and the tuberous sclerosis complex-mTOR pathway

Hepatitis C virus expression suppresses interferon signaling by degrading STAT1

Drug independence and the curability of cancer by combination chemotherapy

Identification of cyclin D1-and estrogen-regulated genes contributing to breast carcinogenesis and progression

hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy

Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System

Cyclin D1 Enhances the Response to Estrogen and Progesterone by Regulating Progesterone Receptor Expression

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

Suchergebnisse filtern